New drug aims to shrink hard-to-treat digestive cancers in early trial
NCT ID NCT06500052
First seen Sep 30, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This early-phase study tests a new drug called BL-M17D1 in about 20 people with advanced HER2-positive or low-HER2 cancers of the digestive tract (esophagus, stomach, pancreas, colon) and other solid tumors. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have tried standard treatments or have no good options left.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.